UoH startup innovates novel stem cell based Covid-19 treatment | India News

HYDERABAD: The latest stem cell based treatment for Covid-19 patients, developed by a startup started at the University of Hyderabad, has emerged as an alternative to virus treatment.
Biotech startup, Transcellucology announced cell-based technology, hemato human umbilical cord (UC) tissue harvesting and clinically processed adult mesenchymal stem cells (MSCs) that have anti-inflammatory and repairing properties.
“From the donated umbilical tissue, we harvested the adult MSc and performed a medical procedure that would reduce the cytokine storm (protein) produced by the virus after infusion into the patient’s body. They reduce the inflammation in the patient’s body caused by the virus, ”said Dr Subhadra Dravida, Founder Chief Executive Officer, Transcell.
As part of this, two intravenous infusions, at a dose of 100 million cells per day, are given at 72-hour intervals for Covid-19 patients. After inspiration, the MSc, as part of their homing mechanism, first reaches the lungs. “They support the regeneration of damaged lungs. Hemato UC-M.Sc. Does not affect any organ, which is easy to operate, proves safe for human application, with the added benefit of not damaging any organ. Dravida said.
The effectiveness of this MSc-based technology has been confirmed by the Cell Transplant Center, Miami Miller School of Medicine, Jackson Health System, USA, Department of Public Health Sciences, pending approval from the Indian Council of Medical Research. Meanwhile, the city has initially teamed up with some of the city’s hospitals to conduct clinical trials of the technology based on compassion.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *